Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Crinetics management to meet with Piper Sandler » 04:55
05/10/23
05/10
04:55
05/10/23
04:55
CRNX

Crinetics

$23.60 /

+1.58 (+7.18%)

Meetings to be held in…

Meetings to be held in Boston on May 8, in Connecticut May 9 and in New York on May 10 hosted by Piper Sandler.

ShowHide Related Items >><<
CRNX Crinetics
$23.60 /

+1.58 (+7.18%)

CRNX Crinetics
$23.60 /

+1.58 (+7.18%)

05/05/23 JMP Securities
Crinetics price target raised to $43 from $41 at JMP Securities
04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
CRNX Crinetics
$23.60 /

+1.58 (+7.18%)

CRNX Crinetics
$23.60 /

+1.58 (+7.18%)

Conference/Events
Crinetics management to meet with Piper Sandler » 05:55
05/09/23
05/09
05:55
05/09/23
05:55
CRNX

Crinetics

$22.02 /

-0.31 (-1.39%)

Meetings to be held in…

Meetings to be held in Boston on May 8, in Connecticut May 9 and in New York on May 10 hosted by Piper Sandler.

ShowHide Related Items >><<
CRNX Crinetics
$22.02 /

-0.31 (-1.39%)

CRNX Crinetics
$22.02 /

-0.31 (-1.39%)

05/05/23 JMP Securities
Crinetics price target raised to $43 from $41 at JMP Securities
04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
CRNX Crinetics
$22.02 /

-0.31 (-1.39%)

CRNX Crinetics
$22.02 /

-0.31 (-1.39%)

Conference/Events
Crinetics management to meet with Piper Sandler » 04:55
05/08/23
05/08
04:55
05/08/23
04:55
CRNX

Crinetics

$22.32 /

+0.96 (+4.49%)

Meetings to be held in…

Meetings to be held in Boston on May 8, in Connecticut May 9 and in New York on May 10 hosted by Piper Sandler.

ShowHide Related Items >><<
CRNX Crinetics
$22.32 /

+0.96 (+4.49%)

CRNX Crinetics
$22.32 /

+0.96 (+4.49%)

05/05/23 JMP Securities
Crinetics price target raised to $43 from $41 at JMP Securities
04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
CRNX Crinetics
$22.32 /

+0.96 (+4.49%)

CRNX Crinetics
$22.32 /

+0.96 (+4.49%)

Recommendations
Crinetics price target raised to $43 from $41 at JMP Securities » 07:25
05/05/23
05/05
07:25
05/05/23
07:25
CRNX

Crinetics

$21.36 /

-0.23 (-1.07%)

JMP Securities analyst…

JMP Securities analyst Jonathan Wolleben raised the firm's price target on Crinetics to $43 from $41 and keeps an Outperform rating on the shares. JMP Securities continues to believe paltusotine will "hit" in PATHFINDR-1 due to results already shown in Phase 2. Meanwhile, success in the PATHFINDR-2 study will be key for broader commercial success. Further, Crinetics remains on track to release Phase 2 data for paltusotine in Q4 and CRN04894, a drug used for congenital adrenal hyperplasia and Cushing's syndrome, next year.

ShowHide Related Items >><<
CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

Earnings
Crinetics reports Q1 EPS (85c), consensus (82c) » 17:56
05/04/23
05/04
17:56
05/04/23
17:56
CRNX

Crinetics

$21.36 /

-0.23 (-1.07%)

Reports Q1 revenue…

Reports Q1 revenue $2.68M, consensus $300,000. "We plan to share topline results from PATHFNDR-1 next quarter, which should provide an important look at the impact that paltusotine may have on patients' lives," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "We designed the two PATHFNDR studies to address both treatment-naive patients as well as patients who may switch from standard of care, the two patient populations specifically outlined in the recently released draft guidance from the FDA on Developing Drugs for Acromegaly Treatment."

ShowHide Related Items >><<
CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

CRNX Crinetics
$21.36 /

-0.23 (-1.07%)

Conference/Events
Crinetics management to meet with Piper Sandler » 07:21
05/03/23
05/03
07:21
05/03/23
07:21
CRNX

Crinetics

$20.90 /

+0.37 (+1.80%)

Meetings to be held in…

Meetings to be held in Boston on May 8, in Connecticut May 9 and in New York on May 10 hosted by Piper Sandler.

ShowHide Related Items >><<
CRNX Crinetics
$20.90 /

+0.37 (+1.80%)

CRNX Crinetics
$20.90 /

+0.37 (+1.80%)

04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
CRNX Crinetics
$20.90 /

+0.37 (+1.80%)

CRNX Crinetics
$20.90 /

+0.37 (+1.80%)

Over a month ago
On The Fly
Biotech Alert: Searches spiking for these stocks today » 11:02
04/26/23
04/26
11:02
04/26/23
11:02
CRNX

Crinetics

$18.31 /

-0.23 (-1.24%)

, IDYA

Ideaya Biosciences

$18.73 /

+0.11 (+0.59%)

, APLT

Applied Therapeutics

$1.45 /

+0.15 (+11.54%)

, AUPH

Aurinia Pharmaceuticals

$10.98 /

-0.095 (-0.86%)

These names in the…

ShowHide Related Items >><<
IDYA Ideaya Biosciences
$18.73 /

+0.11 (+0.59%)

CRNX Crinetics
$18.31 /

-0.23 (-1.24%)

AUPH Aurinia Pharmaceuticals
$10.98 /

-0.095 (-0.86%)

APLT Applied Therapeutics
$1.45 /

+0.15 (+11.54%)

CRNX Crinetics
$18.31 /

-0.23 (-1.24%)

04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
IDYA Ideaya Biosciences
$18.73 /

+0.11 (+0.59%)

04/24/23 Wedbush
Ideaya Biosciences price target raised to $35 from $30 at Wedbush
04/24/23 Oppenheimer
Ideaya Biosciences price target raised to $30 from $26 at Oppenheimer
04/24/23 Guggenheim
Ideaya Biosciences price target raised to $40 from $32 at Guggenheim
04/24/23 Stifel
Ideaya Biosciences upgraded to Buy from Hold at Stifel
APLT Applied Therapeutics
$1.45 /

+0.15 (+11.54%)

04/25/23 Baird
Applied Therapeutics price target lowered to $14 from $18 at Baird
04/05/23 Citi
Applied Therapeutics price target lowered to $5 from $23 at Citi
08/17/22 Citi
Applied Therapeutics price target lowered to $23 from $29 at Citi
AUPH Aurinia Pharmaceuticals
$10.98 /

-0.095 (-0.86%)

04/24/23 Cantor Fitzgerald
Cantor says Aurinia M&A takeout chatter 'picks back up' after MKT letter
01/03/23 RBC Capital
Aurinia price target raised to $11 from $10 at RBC Capital
11/07/22 H.C. Wainwright
Aurinia Pharmaceuticals price target lowered to $14 from $26 at H.C. Wainwright
11/04/22 Oppenheimer
Oppenheimer downgrades Aurinia on commercial challenges
IDYA Ideaya Biosciences
$18.73 /

+0.11 (+0.59%)

CRNX Crinetics
$18.31 /

-0.23 (-1.24%)

AUPH Aurinia Pharmaceuticals
$10.98 /

-0.095 (-0.86%)

APLT Applied Therapeutics
$1.45 /

+0.15 (+11.54%)

  • 25
    Apr
  • 15
    Sep
  • 23
    Jun
AUPH Aurinia Pharmaceuticals
$10.98 /

-0.095 (-0.86%)

IDYA Ideaya Biosciences
$18.73 /

+0.11 (+0.59%)

CRNX Crinetics
$18.31 /

-0.23 (-1.24%)

AUPH Aurinia Pharmaceuticals
$10.98 /

-0.095 (-0.86%)

APLT Applied Therapeutics
$1.45 /

+0.15 (+11.54%)

AUPH Aurinia Pharmaceuticals
$10.98 /

-0.095 (-0.86%)

On The Fly
Fly Intel: Pre-market Movers » 09:03
04/24/23
04/24
09:03
04/24/23
09:03
ARKO

Arko Corp.

$8.48 /

-0.125 (-1.45%)

, CRNX

Crinetics

$17.84 /

+0.71 (+4.14%)

, KO

Coca-Cola

$64.05 /

+0.09 (+0.14%)

, PHG

Philips

$19.04 /

+0.48 (+2.59%)

, BOH

Bank of Hawaii

$48.78 /

-0.805 (-1.62%)

, BBBY

Bed Bath & Beyond

/

+

, TA

TravelCenters

$88.04 /

+0.495 (+0.57%)

, SMCI

Super Micro Computer

$107.39 /

-0.69 (-0.64%)

, BP

BP

$39.64 /

-0.22 (-0.55%)

Check out this morning's…

ShowHide Related Items >><<
TA TravelCenters
$88.04 /

+0.495 (+0.57%)

SMCI Super Micro Computer
$107.39 /

-0.69 (-0.64%)

PHG Philips
$19.04 /

+0.48 (+2.59%)

KO Coca-Cola
$64.05 /

+0.09 (+0.14%)

CRNX Crinetics
$17.84 /

+0.71 (+4.14%)

BP BP
$39.64 /

-0.22 (-0.55%)

BOH Bank of Hawaii
$48.78 /

-0.805 (-1.62%)

BBBY Bed Bath & Beyond
/

+

ARKO Arko Corp.
$8.48 /

-0.125 (-1.45%)

ARKO Arko Corp.
$8.48 /

-0.125 (-1.45%)

03/10/23 BMO Capital
Arko Corp. price target raised to $12 from $10 at BMO Capital
01/09/23 BMO Capital
Arko Corp. price target lowered to $10 from $12 at BMO Capital
05/25/22 Wells Fargo
Arko Corp. initiated with an Equal Weight at Wells Fargo
CRNX Crinetics
$17.84 /

+0.71 (+4.14%)

04/24/23 Piper Sandler
Crinetics initiated with an Overweight at Piper Sandler
03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
KO Coca-Cola
$64.05 /

+0.09 (+0.14%)

04/14/23 Barclays
Coca-Cola price target raised to $72 from $69 at Barclays
04/10/23 Deutsche Bank
Coca-Cola price target raised to $61 from $60 at Deutsche Bank
03/21/23 Argus
Monster Beverage price target raised to $120 from $118 at Argus
03/20/23 Deutsche Bank
Coca-Cola price target lowered to $60 from $63 at Deutsche Bank
PHG Philips
$19.04 /

+0.48 (+2.59%)

04/12/23 Lake Street
iRadimed initiated with a Buy at Lake Street
03/07/23 Bernstein
Philips re-initiated with a Market Perform at Bernstein
01/31/23 Morgan Stanley
Philips price target lowered to EUR 15 from EUR 16 at Morgan Stanley
01/31/23 JPMorgan
Philips price target lowered to EUR 9 from EUR 10.90 at JPMorgan
BOH Bank of Hawaii
$48.78 /

-0.805 (-1.62%)

03/20/23 DA Davidson
Bank of Hawaii price target lowered to $55 from $76 at DA Davidson
01/23/23 Keefe Bruyette
Keefe keeps Market Perform on Bank of Hawaii, says margin likely under pressure
10/25/22 DA Davidson
Bank of Hawaii price target lowered to $76 from $80 at DA Davidson
07/11/22 Jefferies
Bank of Hawaii price target lowered to $79 from $87 at Jefferies
BBBY Bed Bath & Beyond
/

+

04/24/23 Piper Sandler
Bed Bath & Beyond Chapter 11 positive for Target, Walmart, says Piper Sandler
04/24/23 BofA
Bed Bath bankruptcy could be 'modest tailwind' for Wayfair, Overstock, says BofA
02/08/23 Wedbush
Wedbush keeps Underperform on Bed Bath & Beyond, ups price target to 25c
02/08/23 Piper Sandler
Target price target raised to $220 from $200 at Piper Sandler
TA TravelCenters
$88.04 /

+0.495 (+0.57%)

02/17/23 B. Riley
TravelCenters downgraded to Neutral on buyout at B. Riley
02/17/23 Benchmark
TravelCenters downgraded to Hold from Buy at Benchmark
02/17/23 BMO Capital
TravelCenters price target raised to $86 from $60 at BMO Capital
02/17/23 B. Riley
TravelCenters downgraded to Neutral from Buy at B. Riley
SMCI Super Micro Computer
$107.39 /

-0.69 (-0.64%)

04/06/23 Wedbush
Super Micro Computer downgraded to Underperform at Wedbush on near-term risks
04/06/23 Wedbush
Super Micro Computer downgraded to Underperform from Neutral at Wedbush
02/01/23 Northland
Super Micro Computer price target raised to $175 from $165 at Northland
01/11/23 Northland
Super Micro short report presents attractive entry point, says Northland
BP BP
$39.64 /

-0.22 (-0.55%)

04/20/23 Piper Sandler
BP price target lowered to $46 from $47 at Piper Sandler
04/19/23 JPMorgan
BP price target lowered to 570 GBp from 585 GBp at JPMorgan
03/21/23 Morgan Stanley
BP price target lowered to 605 GBp from 660 GBp at Morgan Stanley
02/24/23 JPMorgan
BP price target raised to 585 GBp from 540 GBp at JPMorgan
TA TravelCenters
$88.04 /

+0.495 (+0.57%)

SMCI Super Micro Computer
$107.39 /

-0.69 (-0.64%)

PHG Philips
$19.04 /

+0.48 (+2.59%)

KO Coca-Cola
$64.05 /

+0.09 (+0.14%)

CRNX Crinetics
$17.84 /

+0.71 (+4.14%)

BP BP
$39.64 /

-0.22 (-0.55%)

BOH Bank of Hawaii
$48.78 /

-0.805 (-1.62%)

BBBY Bed Bath & Beyond
/

+

ARKO Arko Corp.
$8.48 /

-0.125 (-1.45%)

KO Coca-Cola
$64.05 /

+0.09 (+0.14%)

BP BP
$39.64 /

-0.22 (-0.55%)

BBBY Bed Bath & Beyond
/

+

TA TravelCenters
$88.04 /

+0.495 (+0.57%)

SMCI Super Micro Computer
$107.39 /

-0.69 (-0.64%)

PHG Philips
$19.04 /

+0.48 (+2.59%)

KO Coca-Cola
$64.05 /

+0.09 (+0.14%)

BP BP
$39.64 /

-0.22 (-0.55%)

BOH Bank of Hawaii
$48.78 /

-0.805 (-1.62%)

BBBY Bed Bath & Beyond
/

+

SMCI Super Micro Computer
$107.39 /

-0.69 (-0.64%)

KO Coca-Cola
$64.05 /

+0.09 (+0.14%)

BP BP
$39.64 /

-0.22 (-0.55%)

BBBY Bed Bath & Beyond
/

+

Initiation
Crinetics initiated with an Overweight at Piper Sandler » 05:48
04/24/23
04/24
05:48
04/24/23
05:48
CRNX

Crinetics

$17.84 /

+0.71 (+4.14%)

Piper Sandler initiated…

Piper Sandler initiated coverage of Crinetics Pharmaceuticals with an Overweight rating and $56 price target. The analyst believes disease acromegaly could be a potential blockbuster market opportunity for the company. Upcoming pivotal trials of PATHFNDR in acromegaly carry low biological, regulatory and clinical risk, the analyst tells investors in a research note. The firm says acromegaly represents a large market opportunity with potential peak sales of over $2B.

ShowHide Related Items >><<
CRNX Crinetics
$17.84 /

+0.71 (+4.14%)

CRNX Crinetics
$17.84 /

+0.71 (+4.14%)

03/29/23 Baird
Baird starts Crinetics with Outperform on 'undervalued asset'
03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
03/01/23 JMP Securities
Crinetics price target lowered to $41 from $50 at JMP Securities
CRNX Crinetics
$17.84 /

+0.71 (+4.14%)

Initiation
Baird starts Crinetics with Outperform on 'undervalued asset' » 16:34
03/29/23
03/29
16:34
03/29/23
16:34
CRNX

Crinetics

$15.97 /

+0.64 (+4.17%)

Baird analyst Brian…

Baird analyst Brian Skorney initiated coverage of Crinetics Pharmaceuticals with an Outperform rating and $48 price target. The analyst like the shares into the company's multiple Phase 2 and 3 data readouts over the next twelve months for its lead drug candidate, paltusotine. The firm sees paltusotine as a "materially undervalued asset" that could become the new standard of care in acromegaly and carcinoid syndrome. Crinetics also has a broad pipeline of early stage assets to complement the lead, the analyst tells investors in a research note.

ShowHide Related Items >><<
CRNX Crinetics
$15.97 /

+0.64 (+4.17%)

CRNX Crinetics
$15.97 /

+0.64 (+4.17%)

03/29/23 Baird
Crinetics initiated with an Outperform at Baird
03/27/23 LifeSci Capital
Crinetics initiated with an Outperform at LifeSci Capital
03/01/23 JMP Securities
Crinetics price target lowered to $41 from $50 at JMP Securities
06/15/22 Evercore ISI
Crinetics added to Best SMID 'Core' Ideas list at Evercore ISI
CRNX Crinetics
$15.97 /

+0.64 (+4.17%)

  • 13
    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.